Toggle Main Menu Toggle Search

Open Access padlockePrints

P06 Adenosine deaminase deficient-severe combined immunodeficiency and multicentric dermatofibrosarcoma protuberans: an emerging association

Lookup NU author(s): William Fostier, Dr Louis Gardner, Dr Fraser Charlton, Dr Anna Dubois, Professor Andrew GenneryORCiD, Dr Suzy Leech

Downloads


Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).


Abstract

© British Association of Dermatologists 2025. Published by Oxford University Press on behalf of British Association of Dermatologists. Adenosine deaminase deficient-severe combined immunodeficiency (ADA-SCID) is an inborn error of immunity characterised by pan-lymphopenia, failure to thrive, severe infections, autoimmunity, and non-immunological organ dysfunction secondary to accumulated cytotoxic adenine metabolites (Kohn et al. 2019). ADA-SCID has been associated with an increased risk of tumour growth, including dermatofibrosarcoma protuberans (DFSP), a locally aggressive fibroblastic neoplasm associated with PDGFB or PDGFD fusions (Gardner et al. 2024). Here, we present a 6-year-old boy with ADA-SCID (treated with family-matched haematopoietic cell transplant (HCT) at age 5 months) with a six-month history of atrophic, roughened, hyperpigmented plaques over his abdomen, back, neck and right medial thigh. Post-transplant, he maintained high donor chimerism (94% donor myeloid and B-lymphocyte; 91% donor T-lymphocyte). Five excision biopsies were performed: all showed a spindle cell lesion in the dermis, with subcutaneous extension in four specimens. Immunohistochemistry revealed diffuse CD34 positivity of the spindle cells, consistent with multicentric DFSP. The tumours demonstrated reduced cellularity and more eosinophilic cytoplasm compared with typical DFSP, findings characteristic of DFSP arising in the context of ADA-SCID. This case highlights the increased incidence and distinct histological features of DFSP in ADA-SCID. Further reporting of cases of DFSP occurring in ADA-SCID is needed to raise clinical awareness and to better define any temporal relationship to enzyme-replacement therapy, HCT or gene therapy. Careful dermatological surveillance is warranted in this patient population. Any new or abnormal skin lesions should prompt early referral, histopathological assessment, and tailored surgical management, preferably with Mohs' micrographic surgery or wide local excision.


Publication metadata

Author(s): Fostier W, Gardner L, Charlton F, Dubois A, Gennery AR, Leech S

Publication type: Article

Publication status: Published

Journal: British Journal of Dermatology

Year: 2025

Volume: 193

Issue: Supplement 3

Online publication date: 19/12/2025

Acceptance date: 02/04/2018

Date deposited: 06/01/2026

ISSN (print): 0007-0963

ISSN (electronic): 1365-2133

Publisher: Oxford University Press

URL: https://doi.org/10.1093/bjd/ljaf465.014

DOI: 10.1093/bjd/ljaf465.014

PubMed id: 41412989


Altmetrics

Altmetrics provided by Altmetric


Share